Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JAZZ 
Jazz Pharmaceuticals PLC (JAZZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: JAZZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $185.53
1 Year Target Price $185.53
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.3% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.65B USD | Price to earnings Ratio - | 1Y Target Price 185.53 |
Price to earnings Ratio - | 1Y Target Price 185.53 | ||
Volume (30-day avg) 18 | Beta 0.34 | 52 Weeks Range 95.49 - 148.06 | Updated Date 08/28/2025 |
52 Weeks Range 95.49 - 148.06 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -7.62 | Actual -8.25 |
Profitability
Profit Margin -9.91% | Operating Margin (TTM) 20.94% |
Management Effectiveness
Return on Assets (TTM) 5.19% | Return on Equity (TTM) -10.84% |
Valuation
Trailing PE - | Forward PE 11.86 | Enterprise Value 11414099579 | Price to Sales(TTM) 1.87 |
Enterprise Value 11414099579 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 2.79 | Enterprise Value to EBITDA 30.66 | Shares Outstanding 60658800 | Shares Floating 58654642 |
Shares Outstanding 60658800 | Shares Floating 58654642 | ||
Percent Insiders 3.12 | Percent Institutions 105.73 |
Upturn AI SWOT
Jazz Pharmaceuticals PLC
Company Overview
History and Background
Jazz Pharmaceuticals PLC was founded in 2003. It has grown through acquisitions and internal development, focusing on specialty pharmaceuticals.
Core Business Areas
- Sleep: Development and commercialization of treatments for sleep disorders like narcolepsy and idiopathic hypersomnia.
- Oncology: Development and commercialization of treatments for hematologic malignancies and solid tumors.
- Movement Disorders: Development and commercialization of treatments for movement disorders.
Leadership and Structure
Bruce Cozadd serves as the Chairman and CEO. The company has a board of directors and operates with functional departments like R&D, Commercial, and Operations.
Top Products and Market Share
Key Offerings
- Xyrem/Xywav: Treatment for narcolepsy. It has a substantial market share within the narcolepsy treatment space, but has faced biosimilar competition since 2023. Competitors include generic versions of sodium oxybate and other stimulant medications.
- Epidiolex/Epidyolex: Cannabidiol oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Jazz acquired this product via the GW Pharma acquisition in 2021. Main competitors are other anti-epileptic drugs such as those made by UCB and Eisai.
- Defitelio/Defitelaza: Treatment for severe hepatic veno-occlusive disease (VOD). Competitors are limited, primarily focusing on supportive care and alternative therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and intense competition. Specialty pharmaceuticals, particularly those targeting rare diseases, often command premium pricing.
Positioning
Jazz Pharmaceuticals PLC is positioned as a specialty pharmaceutical company focused on developing and commercializing innovative treatments for niche markets. Their competitive advantage lies in their focus on specialized areas, strong IP portfolio, and established commercial infrastructure.
Total Addressable Market (TAM)
The total addressable market for Jazz's therapies is estimated to be in the billions of dollars. Jazz is positioned to capture a significant portion of this TAM through continued innovation and commercial excellence.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong intellectual property
- Established commercial infrastructure
- Experience in rare diseases
- Successful acquisition track record
Weaknesses
- Reliance on key products (Xyrem/Xywav)
- Exposure to generic competition
- High debt level (can fluctuate)
- Dependence on successful R&D
- Pricing pressure
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Geographic expansion
- Development of new formulations
- Advancements in drug delivery
Threats
- Generic competition
- Regulatory changes
- Pricing pressure
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TEVA
- LUPIN
- AMPH
Competitive Landscape
Jazz Pharmaceuticals PLC faces competition from both generic and branded pharmaceutical companies. Jazz's advantages include its specialized product portfolio and established commercial infrastructure.
Major Acquisitions
GW Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 7200
- Strategic Rationale: Expanded Jazz's portfolio into cannabinoid-based medicines and broadened its pipeline.
Growth Trajectory and Initiatives
Historical Growth: Jazz Pharmaceuticals PLC has experienced moderate growth over the past several years, driven by acquisitions and organic growth.
Future Projections: Analyst estimates suggest continued growth, driven by new product launches and expansion in existing markets.
Recent Initiatives: Recent strategic initiatives include the launch of new products and expansion into new geographies.
Summary
Jazz Pharmaceuticals is a specialty pharmaceutical company with a strong presence in sleep disorders and oncology. While it has a diversified portfolio, the company faces risks related to generic competition and regulatory changes. Recent acquisitions have expanded Jazz's pipeline, but high debt levels require careful management. Overall, Jazz has moderate strength and stability, but requires a careful and steady hand in management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-01 | President, COO, CEO & Director Ms. Renee D. Gala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.jazzpharma.com |
Full time employees 2800 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.